Aytu BioPharma, Inc. (AYTU)
USD 1.31
(-1.88%)
USD 1.31
(-1.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 15.12 Million USD | -7.53% |
| 2023 | 16.36 Million USD | -10.05% |
| 2022 | 18.18 Million USD | -35.84% |
| 2021 | 28.34 Million USD | 1311.74% |
| 2020 | 2 Million USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 4.6 Million USD | 4522.65% |
| 2013 | 99.51 Thousand USD | 46.22% |
| 2012 | 68.05 Thousand USD | 30.12% |
| 2011 | 52.3 Thousand USD | -32.6% |
| 2010 | 77.59 Thousand USD | 42.08% |
| 2009 | 54.61 Thousand USD | 13.51% |
| 2008 | 48.11 Thousand USD | 39.87% |
| 2007 | 34.4 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q4 | 15.12 Million USD | -52.2% |
| 2024 Q3 | 31.65 Million USD | 97.28% |
| 2024 Q2 | 16.04 Million USD | -0.47% |
| 2024 Q1 | 16.11 Million USD | -1.48% |
| 2023 Q3 | 25.09 Million USD | 13.79% |
| 2023 Q2 | 22.05 Million USD | -2.3% |
| 2023 Q4 | 16.36 Million USD | -34.8% |
| 2023 Q1 | 22.57 Million USD | 24.1% |
| 2023 FY | 16.36 Million USD | -10.05% |
| 2022 Q1 | 25.02 Million USD | -11.72% |
| 2022 FY | 18.18 Million USD | -35.84% |
| 2022 Q4 | 18.18 Million USD | -14.45% |
| 2022 Q3 | 21.26 Million USD | -22.88% |
| 2022 Q2 | 27.57 Million USD | 10.17% |
| 2021 Q4 | 28.34 Million USD | 5.63% |
| 2021 FY | 28.34 Million USD | 1311.74% |
| 2021 Q1 | 1.91 Million USD | -4.51% |
| 2021 Q2 | 1.06 Million USD | -44.47% |
| 2021 Q3 | 26.83 Million USD | 2420.54% |
| 2020 Q2 | 374.56 Thousand USD | -4.89% |
| 2020 Q3 | 4.71 Million USD | 1157.8% |
| 2020 FY | 2 Million USD | 0.0% |
| 2020 Q4 | 2 Million USD | -57.38% |
| 2020 Q1 | 393.81 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | 5.13 Million USD | 1.96% |
| 2019 Q4 | - USD | -100.0% |
| 2019 Q2 | 5.03 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q2 | 4.92 Million USD | 1.99% |
| 2016 Q4 | - USD | -100.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | 4.82 Million USD | 0.0% |
| 2016 Q3 | 9797.00 USD | -99.8% |
| 2015 Q4 | - USD | -100.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q3 | 8 Million USD | 24905.47% |
| 2015 Q2 | 31.99 Thousand USD | 3.25% |
| 2015 Q1 | 30.98 Thousand USD | 8.62% |
| 2014 Q3 | 113.02 Thousand USD | 7.69% |
| 2014 Q4 | 28.52 Thousand USD | -74.76% |
| 2014 Q1 | 99.51 Thousand USD | 3.5% |
| 2014 FY | 4.6 Million USD | 4522.65% |
| 2014 Q2 | 104.95 Thousand USD | 5.47% |
| 2013 Q3 | 83.32 Thousand USD | 0.0% |
| 2013 Q4 | 96.14 Thousand USD | 15.38% |
| 2013 FY | 99.51 Thousand USD | 46.22% |
| 2013 Q1 | 68.05 Thousand USD | 22.78% |
| 2013 Q2 | 83.32 Thousand USD | 22.44% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q2 | 60 Thousand USD | 14.72% |
| 2012 FY | 68.05 Thousand USD | 30.12% |
| 2012 Q1 | 52.3 Thousand USD | -10.63% |
| 2012 Q4 | 55.42 Thousand USD | 0.0% |
| 2011 Q4 | 58.52 Thousand USD | 0.0% |
| 2011 FY | 52.3 Thousand USD | -32.6% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q2 | 50 Thousand USD | -35.57% |
| 2011 Q1 | 77.59 Thousand USD | -3.0% |
| 2010 Q2 | 60 Thousand USD | 9.86% |
| 2010 Q3 | - USD | -100.0% |
| 2010 FY | 77.59 Thousand USD | 42.08% |
| 2010 Q4 | 80 Thousand USD | 0.0% |
| 2010 Q1 | 54.61 Thousand USD | -8.98% |
| 2009 Q1 | 48.11 Thousand USD | 28.31% |
| 2009 Q4 | 60 Thousand USD | 0.0% |
| 2009 Q3 | - USD | -100.0% |
| 2009 Q2 | 49.41 Thousand USD | 2.7% |
| 2009 FY | 54.61 Thousand USD | 13.51% |
| 2008 Q1 | 34.4 Thousand USD | 0.0% |
| 2008 FY | 48.11 Thousand USD | 39.87% |
| 2008 Q4 | 37.5 Thousand USD | 9.01% |
| 2008 Q2 | 34.4 Thousand USD | 0.0% |
| 2008 Q3 | 34.4 Thousand USD | 0.0% |
| 2007 Q4 | 34.4 Thousand USD | 0.0% |
| 2007 FY | 34.4 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 97.203% |
| Theratechnologies Inc. | 58.96 Million USD | 74.344% |
| Safety Shot Inc | 1.54 Million USD | -876.711% |
| Cosmos Health Inc. | 12.42 Million USD | -21.773% |
| Cronos Group Inc. | 2.53 Million USD | -495.644% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 97.886% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 58.349% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 87.324% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -175.953% |
| ProPhase Labs, Inc. | 21.38 Million USD | 29.238% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -2388.322% |
| Dynavax Technologies Corporation | 256.91 Million USD | 94.111% |
| Radius Health, Inc. | 365.31 Million USD | 95.859% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -471.454% |
| Alvotech | 1.07 Billion USD | 98.593% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -2200.271% |
| Alpha Teknova, Inc. | 30.45 Million USD | 50.328% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 10.68% |
| SCYNEXIS, Inc. | 15.08 Million USD | -0.325% |
| Harrow Health, Inc. | 190.5 Million USD | 92.058% |
| Biofrontera Inc. | 5.39 Million USD | -180.219% |
| DURECT Corporation | 20.74 Million USD | 27.075% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 63.568% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 95.202% |
| OptiNose, Inc. | 131.74 Million USD | 88.517% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -1189.763% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 84.691% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 17.904% |
| SIGA Technologies, Inc. | 1.46 Million USD | -933.395% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 88.394% |
| Shineco, Inc. | 29.65 Million USD | 48.986% |
| Phibro Animal Health Corporation | 525.45 Million USD | 97.121% |
| Procaps Group S.A. | 285.93 Million USD | 94.709% |
| TherapeuticsMD, Inc. | 8 Million USD | -88.994% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -25196.37% |
| Viatris Inc. | 18.12 Billion USD | 99.917% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -2200.271% |
| Rockwell Medical, Inc. | 13.43 Million USD | -12.575% |
| Incannex Healthcare Limited | 373 Thousand USD | -3956.032% |
| Tilray Brands, Inc. | 387.31 Million USD | 96.094% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 97.756% |
| PetIQ, Inc. | 468.3 Million USD | 96.769% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 96.468% |
| Journey Medical Corporation | 17.73 Million USD | 14.67% |
| Alimera Sciences, Inc. | 67.39 Million USD | 77.553% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -82.793% |
| Assertio Holdings, Inc. | 40.91 Million USD | 63.021% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -1290.924% |
| Embecta Corp. | 1.63 Billion USD | 99.077% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1364.406% |
| Procaps Group, S.A. | 285.93 Million USD | 94.709% |
| PainReform Ltd. | 86 Thousand USD | -17491.86% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 57.243% |
| Hempacco Co., Inc. | 13.72 Million USD | -10.233% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 97.418% |
| Alvotech | 1.07 Billion USD | 98.593% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 97.548% |
| Kamada Ltd. | 8.74 Million USD | -72.923% |
| Indivior PLC | 281.6 Million USD | 94.628% |
| Currenc Group, Inc. | 31.94 Million USD | 52.638% |
| Evoke Pharma, Inc. | 5 Million USD | -202.58% |
| Flora Growth Corp. | 3.67 Million USD | -312.01% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1364.406% |
| Evolus, Inc. | 126.54 Million USD | 88.045% |
| HUTCHMED (China) Limited | 86.13 Million USD | 82.435% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 97.574% |
| Akanda Corp. | 3.99 Million USD | -278.339% |